Nathan Every, M.D.


A cardiologist by training, Dr. Every has been with Frazier Healthcare Partners since 1999. He has led or co-led exited investments including Biostent (acquired by Abbott), Calibra Medical (acquired by LifeSpan), Rigel Pharmaceuticals (NASDAQ: RIGL), Flowcardia (acquired by C.R. Bard), BARRX, (acquired by Covidien), Ascension Orthopedics (acquired by Integra Lifesciences), Zeltiq (NASDAQ: ZLTQ), Glaukos (NASDAQ: GKOS) and, most recently, Packaging Coordinators Inc. (acquired by The Partners Group). He currently serves on the boards of Correct Care Solutions, Silvergate Pharma, PowerVision, PCI, Leiter’s Compounding Pharmacy, and Abode Healthcare. Prior to joining Frazier, Dr. Every was an associate professor of medicine and the director of the Cardiovascular Outcomes Research Center (CORC) at the University of Washington, where he performed multiple studies evaluating the costs and outcomes of new procedures and pharmaceutical agents. His findings have been published in more than 75 scientific articles, including The New England Journal of Medicine, JAMA and The Lancet.